Global Montelukast Drug Market Insights, Forecast to 2025

2 Global Montelukast Drug Quarterly Market Size Analysis

• 2.1 Montelukast Drug Business Impact Assessment - COVID-19
  • 2.1.1 Global Montelukast Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Montelukast Drug Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Montelukast Drug Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Montelukast Drug Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Montelukast Drug Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Montelukast Drug Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Montelukast Drug Market
• 3.5 Key Manufacturers Montelukast Drug Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Montelukast Drug Segments, By Type

• 4.1 Introduction
  • 1.4.1 Tablet
  • 1.4.2 Chewable tablet
  • 1.4.3 Oral Granules
• 4.2 By Type, Global Montelukast Drug Market Size, 2019-2021
  • 4.2.1 By Type, Global Montelukast Drug Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Montelukast Drug Price, 2020-2021

5 Impact of Covid-19 on Montelukast Drug Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospital
  • 5.5.2 Drug store
  • 5.5.3 Others
• 5.2 By Application, Global Montelukast Drug Market Size, 2019-2021
  • 5.2.1 By Application, Global Montelukast Drug Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Montelukast Drug Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Merck & Co.
  • 7.1.1 Merck & Co. Business Overview
  • 7.1.2 Merck & Co. Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.1.3 Merck & Co. Montelukast Drug Product Introduction
  • 7.1.4 Merck & Co. Response to COVID-19 and Related Developments
• 7.2 Teva
  • 7.2.1 Teva Business Overview
  • 7.2.2 Teva Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.2.3 Teva Montelukast Drug Product Introduction
  • 7.2.4 Teva Response to COVID-19 and Related Developments
• 7.3 Mylan
  • 7.3.1 Mylan Business Overview
  • 7.3.2 Mylan Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.3.3 Mylan Montelukast Drug Product Introduction
  • 7.3.4 Mylan Response to COVID-19 and Related Developments
• 7.4 Glenmark Pharmaceuticals
  • 7.4.1 Glenmark Pharmaceuticals Business Overview
  • 7.4.2 Glenmark Pharmaceuticals Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.4.3 Glenmark Pharmaceuticals Montelukast Drug Product Introduction
  • 7.4.4 Glenmark Pharmaceuticals Response to COVID-19 and Related Developments
• 7.5 Hikma Group
  • 7.5.1 Hikma Group Business Overview
  • 7.5.2 Hikma Group Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.5.3 Hikma Group Montelukast Drug Product Introduction
  • 7.5.4 Hikma Group Response to COVID-19 and Related Developments
• 7.6 Sandoz
  • 7.6.1 Sandoz Business Overview
  • 7.6.2 Sandoz Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.6.3 Sandoz Montelukast Drug Product Introduction
  • 7.6.4 Sandoz Response to COVID-19 and Related Developments
• 7.7 Torrent Pharmaceuticals
  • 7.7.1 Torrent Pharmaceuticals Business Overview
  • 7.7.2 Torrent Pharmaceuticals Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.7.3 Torrent Pharmaceuticals Montelukast Drug Product Introduction
  • 7.7.4 Torrent Pharmaceuticals Response to COVID-19 and Related Developments
• 7.8 Lannett Company
  • 7.8.1 Lannett Company Business Overview
  • 7.8.2 Lannett Company Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.8.3 Lannett Company Montelukast Drug Product Introduction
  • 7.8.4 Lannett Company Response to COVID-19 and Related Developments
• 7.9 Apotex
  • 7.9.1 Apotex Business Overview
  • 7.9.2 Apotex Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.9.3 Apotex Montelukast Drug Product Introduction
  • 7.9.4 Apotex Response to COVID-19 and Related Developments
• 7.10 Dr. Reddys Laboratories
  • 7.10.1 Dr. Reddys Laboratories Business Overview
  • 7.10.2 Dr. Reddys Laboratories Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.10.3 Dr. Reddys Laboratories Montelukast Drug Product Introduction
  • 7.10.4 Dr. Reddys Laboratories Response to COVID-19 and Related Developments
• 7.11 Aurobindo Pharma
  • 7.11.1 Aurobindo Pharma Business Overview
  • 7.11.2 Aurobindo Pharma Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.11.3 Aurobindo Pharma Montelukast Drug Product Introduction
  • 7.11.4 Aurobindo Pharma Response to COVID-19 and Related Developments
• 7.12 Accord Healthcare
  • 7.12.1 Accord Healthcare Business Overview
  • 7.12.2 Accord Healthcare Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.12.3 Accord Healthcare Montelukast Drug Product Introduction
  • 7.12.4 Accord Healthcare Response to COVID-19 and Related Developments
• 7.13 Hetero
  • 7.13.1 Hetero Business Overview
  • 7.13.2 Hetero Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.13.3 Hetero Montelukast Drug Product Introduction
  • 7.13.4 Hetero Response to COVID-19 and Related Developments
• 7.14 Unimark
  • 7.14.1 Unimark Business Overview
  • 7.14.2 Unimark Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.14.3 Unimark Montelukast Drug Product Introduction
  • 7.14.4 Unimark Response to COVID-19 and Related Developments
• 7.15 Ajanta Pharma
  • 7.15.1 Ajanta Pharma Business Overview
  • 7.15.2 Ajanta Pharma Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.15.3 Ajanta Pharma Montelukast Drug Product Introduction
  • 7.15.4 Ajanta Pharma Response to COVID-19 and Related Developments
• 7.16 MACLEODS
  • 7.16.1 MACLEODS Business Overview
  • 7.16.2 MACLEODS Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.16.3 MACLEODS Montelukast Drug Product Introduction
  • 7.16.4 MACLEODS Response to COVID-19 and Related Developments
• 7.17 Jubilant Pharma
  • 7.17.1 Jubilant Pharma Business Overview
  • 7.17.2 Jubilant Pharma Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.17.3 Jubilant Pharma Montelukast Drug Product Introduction
  • 7.17.4 Jubilant Pharma Response to COVID-19 and Related Developments
• 7.18 Unichem Laboratories
  • 7.18.1 Unichem Laboratories Business Overview
  • 7.18.2 Unichem Laboratories Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.18.3 Unichem Laboratories Montelukast Drug Product Introduction
  • 7.18.4 Unichem Laboratories Response to COVID-19 and Related Developments
• 7.19 Amneal Pharmaceuticals
  • 7.19.1 Amneal Pharmaceuticals Business Overview
  • 7.19.2 Amneal Pharmaceuticals Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.19.3 Amneal Pharmaceuticals Montelukast Drug Product Introduction
  • 7.19.4 Amneal Pharmaceuticals Response to COVID-19 and Related Developments
• 7.20 Shanghai Anbison Lab
  • 7.20.1 Shanghai Anbison Lab Business Overview
  • 7.20.2 Shanghai Anbison Lab Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.20.3 Shanghai Anbison Lab Montelukast Drug Product Introduction
  • 7.20.4 Shanghai Anbison Lab Response to COVID-19 and Related Developments
• 7.21 Perrigo
  • 7.21.1 Perrigo Business Overview
  • 7.21.2 Perrigo Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.21.3 Perrigo Montelukast Drug Product Introduction
  • 7.21.4 Perrigo Response to COVID-19 and Related Developments
• 7.22 Cipla
  • 7.22.1 Cipla Business Overview
  • 7.22.2 Cipla Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.22.3 Cipla Montelukast Drug Product Introduction
  • 7.22.4 Cipla Response to COVID-19 and Related Developments
• 7.23 CSPC Ouyi Pharmaceutical
  • 7.23.1 CSPC Ouyi Pharmaceutical Business Overview
  • 7.23.2 CSPC Ouyi Pharmaceutical Montelukast Drug Quarterly Production and Revenue, 2020
  • 7.23.3 CSPC Ouyi Pharmaceutical Montelukast Drug Product Introduction
  • 7.23.4 CSPC Ouyi Pharmaceutical Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Montelukast Drug Supply Chain Analysis
  • 8.1.1 Montelukast Drug Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Montelukast Drug Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Montelukast Drug Distribution Channels
  • 8.2.2 Covid-19 Impact on Montelukast Drug Distribution Channels
  • 8.2.3 Montelukast Drug Distributors
• 8.3 Montelukast Drug Customers

9 Key Findings

10 Appendix

• 10.1 About Us